All In Biotech

Drug Trial Radar · NCT05372614

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Oct 5, 2022

Primary completion

Jul 17, 2028

Study completion Jul 17, 2028

Sponsor

Sponsor type
NIH
First posted
May 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene.

Conditions

  • Metastatic Malignant Solid Neoplasm
  • Metastatic Pancreatic Adenocarcinoma
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Pancreatic Adenocarcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • Echocardiography TestProcedure

    Undergo echocardiography

  • Multigated Acquisition ScanProcedure

    Undergo MUGA scan

  • Neratinib MaleateDrug

    Given PO

  • Trastuzumab DeruxtecanBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (Part 1, Dose Escalation)Time frame: In the first 2 cycles in dose escalation of combination of neratinib and trastuzumab deruxtecan (DS-8201a) (cycle length = 21 days)
  2. Incidence of treatment-emergent adverse events (Part 1, Dose Escalation)Time frame: In the first 2 cycles of combination of neratinib and DS-8201a (cycle length = 21 days)
  3. Objective response rate (ORR) (Part 2, Pancreatic Cohort)Time frame: Up to 1 year

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Suspended

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Suspended

  • City of Hope Upland

    Upland, California · Suspended

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Suspended

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin · Recruiting

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.